Four Reverse Splits in Three Weeks: Inside the Small-Cap Listing-Compliance Treadmill

by Daniel Brenner · August 27, 2026

Senior Markets Analyst, The SmallCap Signal

Four micro-cap issuers have executed or scheduled reverse stock splits inside a three-week window, and in every case the stated purpose was the same: get the closing bid price back above a dollar and keep, or obtain, a Nasdaq listing. Read individually, each is a routine corporate action. Read together, and against the rulebook changes Nasdaq has pushed through since 2021, they show a compliance mechanism that has become considerably less forgiving.

Onfolio: 42 million shares to 850,000

Onfolio Holdings, a holding company for online businesses, announced on Aug. 6 a 1-for-50 reverse split effective Monday, Aug. 10, according to a StockTitan summary of the company's release. The consolidation took shares outstanding from roughly 42 million to roughly 850,000, with fractional shares rounded up and no shareholder action required. The stated aim was to lift the closing bid above $1.00 and cure a deficiency under Nasdaq Listing Rule 5550(a)(2).

On Thursday, Aug. 27, the company said Nasdaq had confirmed it regained compliance with Listing Rule 5550(a)(2), having posted a closing bid price at or above $1.00 for ten consecutive business days. "We enacted our reverse-split two weeks ago specifically to regain Nasdaq compliance," chief executive Dominic Wells said in the release. "With that compliance restored, we can focus on our growth and acquisition strategy and put this compliance matter behind us." Onfolio's common stock and warrants trade as ONFO and ONFOW, with a preferred series quoted over the counter as ONFOP. Worth noting: a ratio that leaves roughly 850,000 shares outstanding solves the price test by shrinking the float to a size at which even modest trading volume can move the quote sharply. The company's release flagged continued-listing compliance and stock-price volatility among its forward-looking risks.

Interpace is running the play in reverse - to get on, not stay on

Interpace Biosciences took the same mechanical step for the opposite reason. The molecular diagnostics company announced on Aug. 26 a 1-for-5 reverse split effective at 12:01 a.m. Eastern on Aug. 27, cutting shares outstanding from about 27.7 million to about 5.5 million, per the company's release. Interpace currently trades on OTCID under IDXG and will carry the temporary symbol IDXGD for 20 trading days.

The goal here is an uplisting to Nasdaq rather than a cure. "This reverse stock split is a key part of our strategy to uplist our common stock to Nasdaq, which we believe will help support our planned growth and attract a broader range of investors," chief executive Tom Burnell said in the release - a management view, not an outcome. The release itself stated that "there is no guarantee that the Company will meet the minimum bid price requirement, and even if it does, there are additional requirements for listing on Nasdaq, including the requirement to have a $15 million market value of unrestricted publicly held shares."

That $15 million threshold is the harder gate. A price test can be engineered with a ratio; a market-value-of-public-float test cannot. With roughly 5.5 million shares outstanding post-split, the arithmetic required to clear it is not trivial, and the company did not state in the release how close it is.

Two more this week

Cycurion, a cybersecurity company, said in a release datelined McLean, Va., Aug. 26 - reviewed here via a StockTitan summary - that a 1-for-8 reverse split becomes effective at the open on Friday, Aug. 28, taking shares outstanding from approximately 25,840,335 to approximately 3,230,041. The company said the move is intended, among other things, to help it maintain compliance with the minimum bid price requirement for continued listing on the Nasdaq Global Market. Fractional shares will be cashed out at the prior day's closing price.

Glucotrack, a medical device developer, announced on Aug. 27, in a release carried on Business Wire and read here via a StockTitan summary, a 1-for-15 reverse split effective at the opening of trading Monday, Aug. 31, reducing shares outstanding from 11,972,157 to approximately 798,144. The company disclosed a specific deadline: it must maintain a closing bid price of at least $1.00 through Nov. 9, 2026, or face possible delisting from the Nasdaq Capital Market.

Why the second bite is harder than it used to be

The reason these splits matter more than they once did is that Nasdaq has spent five years narrowing the escape hatch. In a Sept. 3, 2025 announcement of further proposed listing standard changes, the exchange recapped its own recent tightening: a September 2021 measure that limited companies' ability to effect excessive reverse stock splits and allowed the exchange to move a company into the delisting process immediately if its share price is below $0.10 for ten consecutive trading days; an October 2024 change that "further limited the time provided to companies to cure a listing deficiency if that deficiency was caused by a reverse split enacted to regain compliance with bid price requirements"; and a January 2025 change that, in the exchange's words, "decreased the time a company could trade on Nasdaq while below $1 to 360 days and prohibited further compliance periods to any company that effected a reverse stock split within the prior year." That last provision is what turns a reverse split from a repeatable maneuver into something closer to a single attempt: a company that consolidates, drifts back below a dollar within twelve months and finds itself deficient again does not get a fresh 180-day grace window under the framework Nasdaq described.

The September 2025 proposals went further still, per the exchange's announcement: a $15 million minimum market value of public float for new listings under the net income standard, a $25 million minimum public offering proceeds requirement for companies principally operating in China, and an accelerated suspension and delisting process for companies that are both deficient and carrying a market value of listed securities below $5 million. Nasdaq filed these as SR-NASDAQ-2025-068 and SR-NASDAQ-2025-069. John Zecca, the exchange's executive vice president and global chief legal, risk and regulatory officer, said in the announcement: "Investor protection and market integrity are central to Nasdaq's mission." Those items were characterized as proposals subject to SEC approval, with the initial-listing pieces to take effect promptly after approval - and a 30-day grace period for companies already in process - and the accelerated delisting provisions 60 days after approval. This article did not independently confirm their current approval status, and readers should check the rule filings before assuming any of them is in force.

What to watch

The near-term test dates are concrete. Cycurion's split-adjusted shares begin trading Aug. 28 and Glucotrack's on Aug. 31, with Glucotrack facing a stated Nov. 9 bid-price deadline. Interpace's uplisting attempt turns less on its Aug. 27 consolidation than on whether it can satisfy the public-float value test its own release named. And Onfolio, having cleared its deficiency, now has roughly twelve months in which a slip back below a dollar would arrive without the cushion earlier issuers enjoyed.